Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis-2 "ASPECT-2"


Phase N/A Results

Trial Description

To determine the long term efficacy of aspirin and oral anticoagulants in reducing ischemic events after acute coronary events.


Trial Design

Prospective, multicenter, randomized open-label trial.

Patient Involvement

Patients were randomized into 3 groups to receive either aspirin (80 mg) (n=336), oral anticoagulants (target INR 3.0-4.0) (n=325) or oral anticoagulants (target INR 2.0-2.50 plus aspirin (80 mg) (n=332). An assessment questionnaire was completed every 3 months.


Type Measure Time Frame Safety Issue
Primary Death, time to myocardial infarction or stroke.
Secondary Death from all causes, episodes of bleeding.


The Netherlands National Health Insurance Fund Council